<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126744">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01452412</url>
  </required_header>
  <id_info>
    <org_study_id>CCI-2009-408</org_study_id>
    <secondary_id>R01DK087783</secondary_id>
    <nct_id>NCT01452412</nct_id>
  </id_info>
  <brief_title>Alkali Therapy in Chronic Kidney Disease</brief_title>
  <official_title>Placebo-controlled Randomized Clinical Trial of Alkali Therapy in Patients With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Kidney disease is a common medical condition. Individuals with kidney disease develop a
      build-up of acid in their blood. This acid can affect their muscles, bones, glucose
      metabolism and kidneys. The investigators will test alkali treatment, to treat acid
      build-up, in a randomized placebo-controlled clinical trial to evaluate effects on muscles,
      bones, glucose metabolism and kidney.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>1 year</time_frame>
    <description>Fasting bloods will be drawn to calculate a HOMA-IR score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sit to stand to sit speed</measure>
    <time_frame>1 year</time_frame>
    <description>Sit to stand to sit x10 speed will be measured and compared between groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DEXA of wrist</measure>
    <time_frame>1 year</time_frame>
    <description>The investigators will evaluate changes in bone mineral density at the wrist.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary NGAL and KIM-1</measure>
    <time_frame>1 year</time_frame>
    <description>The investigators will evaluate biomarkers of kidney tubular function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose disposal rate by euglycemic hyperinsulinemic clamp</measure>
    <time_frame>2 months</time_frame>
    <description>30 participants will undergo insulin clamp procedure to assess insulin sensitivity at baseline and 2 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand-grip strength</measure>
    <time_frame>1 year</time_frame>
    <description>Hand-grip strength will be measured in all participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum PTH</measure>
    <time_frame>1 year</time_frame>
    <description>Parathyroid hormone levels will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone-specific alkaline phosphatase</measure>
    <time_frame>1 year</time_frame>
    <description>Bone-specific alkaline phosphatase will be assessed in all participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum calcium</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum phosphate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum 1,25-dihydroxyvitamin D</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum creatinine</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum cystatin C</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary albumin/ creatinine ratio</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary cystatin</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Metabolic Acidosis</condition>
  <arm_group>
    <arm_group_label>Sodium bicarbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium bicarbonate</intervention_name>
    <description>0.4 mEq/kg/day ideal body weight to be taken once a day</description>
    <arm_group_label>Sodium bicarbonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>To be taken on the same schedule as the active arm</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Estimate GFR &lt;= 45 and &gt;15 ml/min/1.73m2

          -  Age &gt;18

        Exclusion Criteria:

          -  Previous chronic treatment with alkali within the last 3 months (including sodium
             bicarbonate, calcium carbonate or baking soda)

          -  bicarbonate level &lt;20 or &gt;25 mEq/L

          -  New York Heart Association Class III or IV heart failure

          -  Systolic blood pressure &gt;180 mmHg

          -  Initiation of ESRD treatment planned within 6 months

          -  Kidney transplantation

          -  Treatment with immunosuppressives within the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Hostetter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Western Reserve University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisandra Ninonuevo</last_name>
    <phone>718-430-3301</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisandra Ninonuevo</last_name>
      <phone>718-430-3301</phone>
    </contact>
    <contact_backup>
      <last_name>Michal Melamed, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Michal L Melamed, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Abramowitz, MD, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Thomas Hostetter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 28, 2016</lastchanged_date>
  <firstreceived_date>October 12, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine of Yeshiva University</investigator_affiliation>
    <investigator_full_name>Michal L. Melamed</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Alkali</keyword>
  <keyword>Sodium bicarbonate</keyword>
  <keyword>Kidney disease</keyword>
  <keyword>Acidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Acidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
